In a couple of small, phase-2 clinical studies in hypertensive patients, IONIS-AGT-LRx was administered by weekly subcutaneous injections, either as a monotherapy in patients with controlled BP (NCT03714776) or as an add-on therapy in patients with uncontrolled hypertension (NCT04083222). The gene discussed is AGT; the disease is hypertensive disorder.